Read more in the app
Research reveals high-risk subtype of relapsed pediatric AML
For children, young adults with recurrent AML, immunotherapy shows promise
Oncotarget: Fgr and Numb in retinoic differentiation and G0 arrest of non-APL AML cells
Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML
Oncotarget: Activation of plasmacytoid dendritic cells promotes AML-cell fratricide
Investigational combo therapy shows benefit for TP53 mutant MDS and AML patients
New drug combination shows promise as powerful treatment for AML
